Table 1.
Comp. | Vero-76 cells | RSV | Comp. | Vero-76 cells | RSV |
---|---|---|---|---|---|
a CC50 | bEC50 | aCC50 | bEC50 | ||
1a | >100 | 20 | 8a | >100 | >100 |
5a | 30 | 3 | 8b | >100 | 27 |
5b | 30 | 4 | 8c | >100 | >100 |
5c | 10 | 4 | 8d | 80 | 3 |
5d | 20 | >30 | 8e | >100 | 33 |
7a | >100 | 60 | 8f | 80 | 20 |
7b | >100 | >100 | 8g | >100 | 50 |
7c | >100 | 35 | 8h | >100 | 60 |
7d | 90 | 5 | 10a | >100 | >100 |
7e | >100 | 13 | 10b | 30 | 3 |
7f | >100 | 8 | 10c | >100 | >100 |
7g | 9 | 5 | 10d | 90 | 2 |
7h | >100 | 11 | 10e | >100 | >100 |
1b | >100 | 6 | 10f | >100 | >100 |
6a | >100 | >100 | 10g | >100 | >100 |
6b | >100 | >100 | 10h | >100 | >100 |
6c | >100 | >100 | 10i | >100 | >100 |
6d | >100 | 40 | 10j | >100 | >100 |
6e | >100 | 6 | 10k | >100 | >100 |
6f | >100 | 6 | ribavirin | >100 | 7 |
6-azauridine | ≥14 | 1.4 |
Ribavirin and 6-azauridine were used as reference inhibitors. Data represent mean values from three independent determinations; variation among duplicate samples was <15%.
Compound concentration (μM) required to reduce the viability of mock-infected VERO-76 cells by 50%. as determined by the MTT method after 5 days.
Compound concentration (μM) required to reduce the plaque number of RSV by 50% in VERO-76 monolayers. The most interesting results are in bold.